Proteomic alterations in patients with atopic dermatitis
A Obi, C Rothenberg-Lausell, S Levit… - Expert Review of …, 2024 - Taylor & Francis
Introduction AtopicDermatitis (AD) is the most common inflammatory skin disease with a
complex andmultifactorial pathogenesis. The use of proteomics in understanding AD …
complex andmultifactorial pathogenesis. The use of proteomics in understanding AD …
[HTML][HTML] Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis
D Pavlenko, ZT Seven, L Bystrom… - Acta dermato …, 2023 - ncbi.nlm.nih.gov
Abstract Crisaborole, a phosphodiesterase 4 (PDE4) inhibitor, has been approved for the
treatment of mild to moderate atopic dermatitis. Atopic dermatitis is often associated with …
treatment of mild to moderate atopic dermatitis. Atopic dermatitis is often associated with …
Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis
LF Eichenfield, LF Stein Gold, C Lynde… - Dermatology and …, 2024 - Springer
Introduction Treatments for atopic dermatitis (AD) often fail to achieve lasting disease
control. In the CrisADe CONTROL phase III study (ClinicalTrials. gov: NCT04040192) …
control. In the CrisADe CONTROL phase III study (ClinicalTrials. gov: NCT04040192) …
CLDR: Contrastive Learning Drug Response Models from Natural Language Supervision
K Li, W Hu - arXiv preprint arXiv:2312.10707, 2023 - arxiv.org
Deep learning-based drug response prediction (DRP) methods can accelerate the drug
discovery process and reduce R\&D costs. Although the mainstream methods achieve high …
discovery process and reduce R\&D costs. Although the mainstream methods achieve high …